S. Bologna

发表

Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study

G. Salles, R. Bouabdallah, A. Stamatoullas, 2015 .

Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study.

T. Molina, B. Coiffier, H. Tilly, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.

J. Raemaekers, A. Allgeier, E. Noordijk, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

H. Dombret, A. Delannoy, M. Béné, 2006, Leukemia.

Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study

A. Stamatoullas, O. Casasnovas, N. Mounier, 2015, Haematologica.

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

T. Molina, F. Jardin, G. Salles, 2011, The Lancet.

ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.

B. Coiffier, N. Mounier, P. Lugtenburg, 2012 .

Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.

G. Salles, J. Benichou, R. Bouabdallah, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).

B. Coiffier, O. Casasnovas, H. Tilly, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma ( LNH 03-1 B )

er, O. Casasnovas, H. Tilly, 2013 .

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

T. Molina, F. Jardin, G. Salles, 2011, The Lancet.

Impact of rituximab on stem cell mobilization following ACVBP regimen in poor‐risk patients with diffuse large B‐cell lymphoma: results from a large cohort of patients

G. Salles, H. Tilly, N. Mounier, 2013, Transfusion.

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.

B. Coiffier, O. Casasnovas, H. Tilly, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA)

P. Gaulard, B. Coiffier, H. Tilly, 2010 .

Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial

M. Béné, N. Ifrah, J. Harousseau, 2007, Haematologica.

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

A. Barać, L. Pagano, B. Drénou, 2021, Journal of Hematology & Oncology.

Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study.

J. Raemaekers, A. Allgeier, E. Noordijk, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

B. Coiffier, J. Jais, C. Haioun, 2011, Blood.

A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B

T. Molina, F. Jardin, B. Coiffier, 2010 .

Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study

M. Bernard, P. Chevallier, Y. Gruel, 2008, Haematologica.

Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.

P. Gaulard, B. Coiffier, H. Tilly, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

F. Jardin, P. Gaulard, B. Coiffier, 2011, The Lancet. Oncology.

Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial.

J. Briones, M. Federico, M. Petrini, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy

P. Feugier, B. Drénou, S. Choquet, 2021, American journal of hematology.

Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

B. Coiffier, F. Morschhauser, O. Casasnovas, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

P. Gaulard, G. Salles, A. Rahmouni, 2013, Haematologica.

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Catherine Thieblemont, Nicolas Mounier, Richard Delarue, 2013, The Lancet. Oncology.

Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).

T. Molina, B. Coiffier, J. Jais, 2014 .

(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.

B. Coiffier, H. Tilly, C. Gisselbrecht, 2011, Clinical lymphoma, myeloma & leukemia.

Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study

G. Salles, O. Casasnovas, H. Tilly, 2014 .

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma

J. Cerhan, R. Gascoyne, C. Copie-Bergman, 2016, American journal of hematology.

Idiotype as a tumor-specific marker in childhood B cell acute lymphoblastic leukemia.

S. Smith, M. Amylon, M. Cleary, 1988, Blood.

Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study

B. Drénou, S. Choquet, C. Soussain, 2020, EClinicalMedicine.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

F. Jardin, B. Coiffier, H. Tilly, 2017, The Lancet. Haematology.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

J. Raemaekers, G. Salles, D. de Jong, 2017, European journal of cancer.

THE LONG-TERM OUTCOME OF ELDERLY PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH plus ALL) IN THE IMATINIB ERA

H. Dombret, A. Delannoy, M. Béné, 2009 .

[A case of de novo acute basophilic leukaemia: diagnostic criteria and review of the literature].

P. Jonveaux, T. Lecompte, V. Latger‐Cannard, 2006, Annales de biologie clinique.

MONOMORPHIC EPITHELIOTROPIC INTESTINAL T‐CELL LYMPHOMA (MEITL): CLINICO‐PATHOLOGICAL ANALYSIS OF A MULTICENTER EUROPEAN COHORT

P. Gaulard, L. Xerri, M. Copin, 2021, Hematological Oncology.

Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study.

T. Molina, G. Salles, R. Bouabdallah, 2013, Clinical advances in hematology & oncology : H&O.

Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LNH98-B3 GELA study

B. Coiffier, H. Tilly, C. Gisselbrecht, 2007 .

Identification of an Acute Basophilic Leukaemia Carrying a Rare e6a2 BCR-ABL Transcript

P. Jonveaux, A. Staal, V. Latger‐Cannard, 2006, Acta Haematologica.

ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.

O. Casasnovas, N. Mounier, M. André, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

B. Coiffier, J. Jais, C. Haioun, 2011, Blood.

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma

J. Cerhan, R. Gascoyne, C. Copie-Bergman, 2016, American journal of hematology.